The Science of Biological Reset

Your DNA sequence doesn't change as you age. Your epigenome does. Methylation marks — chemical tags that control gene expression — drift from their youthful patterns in a predictable, measurable way. Horvath's epigenetic clock, published in 2013, showed this drift correlates with biological age more accurately than any other biomarker.

This drift is not random noise. It is a program running in reverse — or rather, a maintenance program that gradually fails. The question is not why the clock runs. The question is whether we can reset it.

In 2006, Shinya Yamanaka discovered that expressing Oct4, Sox2, Klf4, and c-Myc (OSKM) in a fibroblast would return it to a pluripotent state — a blank cellular slate. His 2012 Nobel Prize validated both the discovery and its implications. But full reprogramming destroys the cell's acquired identity — the epigenetic memory that makes a liver cell a liver cell.

Partial reprogramming solves this. By delivering OSK (without MYC, which is oncogenic) in transient pulses, we can reverse methylation age markers without inducing full pluripotency. The cell stays what it is. It just becomes a younger version of itself.

Our platform combines three integrated systems: a next-generation OSK delivery vehicle (mRNA-LNP with tissue-specific targeting), a real-time epigenomic monitoring layer (methylation sequencing at single-cell resolution), and an AI-driven pulse controller that halts expression the moment preset safety thresholds are approached.

The result is a closed-loop reprogramming system — the first of its kind. We reprogram with feedback, not blind expression. Every cycle is validated. Every organ response is monitored. This is what makes partial reprogramming not just scientifically possible, but clinically viable.

Safety is not a feature of our platform. It is the foundation. We operate under a principle we call Minimum Effective Reprogramming — the smallest epigenetic intervention that produces measurable age reversal. Our kill switch system, encoded directly into the delivery vehicle, terminates factor expression on four independent signals: time-gated circuits, methylation threshold sensors, tissue stress markers, and manual override.

No single failure mode can produce runaway reprogramming. The system is redundant by design.

In mouse models, our OSK pulse protocol has demonstrated up to 47% reversal of methylation age (measured by the Petkovich clock), with sustained benefits at 12-week follow-up. We observe improvements in grip strength, cognitive performance on maze tasks, retinal ganglion cell function, and kidney fibrosis markers — across multiple cohorts and delivery routes.

* These results are preclinical. Human translation involves additional validation. Phase I trials are targeted for 2028-2030 pending regulatory designation.